- Home
- KZIA vs THAR Comparison
KZIA vs THAR Comparison
Compare KZIA & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- THAR
- Stock Information
- Founded
- KZIA 1994
- THAR 2017
- Country
- KZIA Australia
- THAR United States
- Employees
- KZIA N/A
- THAR N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- THAR Health Care
- Exchange
- KZIA Nasdaq
- THAR Nasdaq
- Market Cap
- KZIA 5.1M
- THAR 5.5M
- IPO Year
- KZIA 1999
- THAR 2022
- Fundamental
- Price
- KZIA $10.45
- THAR $1.78
- Analyst Decision
- KZIA Strong Buy
- THAR Strong Buy
- Analyst Count
- KZIA 2
- THAR 1
- Target Price
- KZIA $14.00
- THAR $17.00
- AVG Volume (30 Days)
- KZIA 745.7K
- THAR 41.3K
- Earning Date
- KZIA 07-22-2025
- THAR 08-08-2025
- Dividend Yield
- KZIA N/A
- THAR N/A
- EPS Growth
- KZIA N/A
- THAR N/A
- EPS
- KZIA N/A
- THAR N/A
- Revenue
- KZIA $1,549,158.00
- THAR N/A
- Revenue This Year
- KZIA N/A
- THAR N/A
- Revenue Next Year
- KZIA N/A
- THAR N/A
- P/E Ratio
- KZIA N/A
- THAR N/A
- Revenue Growth
- KZIA 248983.08
- THAR N/A
- 52 Week Low
- KZIA $2.86
- THAR $0.95
- 52 Week High
- KZIA $79.00
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- KZIA 72.75
- THAR 57.46
- Support Level
- KZIA $5.86
- THAR $1.60
- Resistance Level
- KZIA $7.20
- THAR $1.88
- Average True Range (ATR)
- KZIA 1.17
- THAR 0.15
- MACD
- KZIA 0.15
- THAR 0.01
- Stochastic Oscillator
- KZIA 82.21
- THAR 71.21
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.